Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

ClinicalTrials.gov ID: NCT01359566

Public ClinicalTrials.gov record NCT01359566. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to placebo for the treatment of spasticity in subjects with multiple sclerosis (MS).

Study identification

NCT ID
NCT01359566
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
XenoPort, Inc.
Industry
Enrollment
228 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2011
Primary completion
Jan 31, 2013
Completion
Jan 31, 2013
Last update posted
Feb 20, 2021

2011 – 2013

United States locations

U.S. sites
28
U.S. states
18
U.S. cities
28
Facility City State ZIP Site status
XenoPort Clinical Site Phoenix Arizona 85004
XenoPort Clinical Site Tucson Arizona 85701
XenoPort Clinical Site Berkeley California 94705
XenoPort Clinical Site San Diego California 92103
XenoPort Clinical Site Denver Colorado 80012
XenoPort Clinical Site Port Charlotte Florida 33948
XenoPort Clinical Site Sarasota Florida 34231
XenoPort Clinical Site St. Petersburg Florida 33701
XenoPort Clinical Site Tampa Florida 33604
XenoPort Clinical Site Lake Barrington Illinois 60010
XenoPort Clinical Site Indianapolis Indiana 46204
XenoPort Clinical Site Lenexa Kansas 66210
XenoPort Clinical Site Lexington Kentucky 40505
XenoPort Clinical Site Bingham Farms Michigan 48025
XenoPort Clinical Site Detroit Michigan 48202
XenoPort Clinical Site Toms River New Jersey 08753
XenoPort Clinical Site Albuquerque New Mexico 87102
XenoPort Clinical Site Albany New York 12208
XenoPort Clinical Site Patchogue New York 11772
XenoPort Clinical Site Plainview New York 11803
XenoPort Clinical Site Asheville North Carolina 28805
XenoPort Clinical Site Akron Ohio 44320
XenoPort Clinical Site Franklin Tennessee 37064
XenoPort Clinical Site Nashville Tennessee 37205
XenoPort Clinical Site San Antonio Texas 78206
XenoPort Clinical Site Vienna Virginia 22181
XenoPort Clinical Site Seattle Washington 98108
XenoPort Clinical Site Tacoma Washington 98404

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01359566, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 20, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01359566 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →